Eli Lilly’s weight loss medication achieves success in initial late-stage trial involving diabetes patients.
Eli Lilly announced on Thursday that its daily obesity pill successfully achieved the company’s objectives in the first of several late-stage trials. This new medication helps patients with Type 2 diabetes reduce their blood sugar levels and body weight, demonstrating a safety profile comparable to popular injectable treatments currently available. The trial results represent one of the most closely monitored studies in the pharmaceutical industry this year, as Eli Lilly’s experimental pill — known as orforglipron — moves closer to becoming a new, needle-free option in the rapidly expanding market for weight loss and diabetes solutions.
This straightforward, easy-to-manufacture pill may provide Eli Lilly with a significant advantage over competitors like Novo Nordisk and others striving to enter this lucrative sector. The weight loss results, along with the rates of side effects and treatment discontinuances, aligned with Wall Street analysts’ expectations, although orforglipron did not meet some predictions regarding an important diabetes metric. The highest dosage of the pill enabled patients to lose an average of 7.9% of their weight, approximately 16 pounds, after 40 weeks, and Eli Lilly noted that there was no plateau in weight loss by the study’s conclusion, indicating that further weight loss might be possible beyond that period.
Prior studies have indicated that diabetic patients tend to lose less weight than those without diabetes, complicating comparisons of this data to medications specifically designed for obesity. Approximately 8% of patients at the highest dosage discontinued the treatment due to side effects, mainly gastrointestinal, such as mild to moderate nausea and vomiting. Among those, 14% experienced vomiting, while 16% and 26% reported nausea and diarrhea, respectively.
TD Cowen analysts recently projected a 9% discontinuation rate. Some experts anticipated that side effects from the pill might be slightly more pronounced than those from injections, given its daily administration compared to weekly injections. However, orforglipron did not meet some analysts’ expectations regarding a crucial diabetes metric, managing to reduce hemoglobin A1c—a key measure of blood sugar levels—by an average of 1.3% to 1.6% across varying doses over 40 weeks, starting from an 8% baseline. In contrast, patients receiving a placebo observed a mere 0.1% reduction during the same period. Some analysts had forecasted reductions between 1.8% and 2.1%, comparable to results from patients who used Novo Nordisk’s diabetes injection Ozempic.
Still, Eli Lilly’s CEO David Ricks expressed satisfaction that the latest incretin medicine met the company’s expectations regarding safety, tolerability, glucose control, and weight loss. The company is looking forward to additional data appearances later this year. Incretin drugs act by mimicking certain gut hormones to curb appetite and regulate blood sugar levels.
Currently, there are seven late-stage studies focusing on the pill—five targeting diabetes and two aimed at obesity. Eli Lilly anticipates submitting for regulatory approval for the obesity indication by the end of the year, with a follow-up for diabetes projected in 2026. If approved, orforglipron could broaden access to treatment and help alleviate shortages of popular injectable medications. The pill could be produced and distributed on a large scale for use globally, as stated by Ricks.
This oral medication might further bolster Eli Lilly’s standing in the burgeoning market, especially as various other pharmaceutical companies race to develop similar products. Being the first to offer an oral version of the GLP-1 class could enable Eli Lilly to capture a larger slice of this sought-after market for weight loss and diabetes drugs. Analysts suggest that Eli Lilly is currently years ahead of competitors in the development of oral medications, leading other companies like AstraZeneca, Roche, Structure Therapeutics, and Viking Therapeutics.
With the market for GLP-1 medications anticipated to exceed $150 billion annually by the early 2030s, oral GLP-1s could account for an estimated $50 billion of that overall figure, according to some analysts. Eli Lilly’s pill operates similarly to Wegovy, Ozempic, and Novo Nordisk’s diabetes pill Rybelsus, targeting the GLP-1 hormone to decrease appetite and control blood sugar levels. However, unlike those three medications, Eli Lilly’s pill is not a peptide medication, which facilitates easier absorption by the body and avoids the dietary restrictions associated with Rybelsus.
